Skip to main content
SpringerLink
Log in

Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial

  • Short Communication
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720

    Article  CAS  PubMed  Google Scholar 

  2. Verma S, Mazer CD, Yan AT et al (2019) Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease. Circulation 140(21):1693–1702. https://doi.org/10.1161/CIRCULATIONAHA.119.042375

    Article  PubMed  Google Scholar 

  3. Kawaji K, Codella NCF, Prince MR et al (2009) Automated segmentation of routine clinical cardiac magnetic resonance imaging for assessment of left ventricular diastolic dysfunction. Circ Cardiovasc Imag 2(6):476–484. https://doi.org/10.1161/CIRCIMAGING.109.879304

    Article  Google Scholar 

  4. Januzzi JL, Xu J, Li J et al (2020) Effects of canagliflozin on amino-terminal pro–B-type natriuretic peptide: implications for cardiovascular risk reduction. J Am Coll Cardiol 76(18):2076–2085. https://doi.org/10.1016/j.jacc.2020.09.004

    Article  CAS  PubMed  Google Scholar 

  5. Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. https://doi.org/10.1056/NEJMoa2107038

    Article  PubMed  Google Scholar 

  6. Shim CY, Jiwon S, Iksung C et al (2021) Randomized, controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus. Circulation 143(5):510–512. https://doi.org/10.1161/CIRCULATIONAHA.120.051992

    Article  CAS  PubMed  Google Scholar 

  7. Bami K, Gandhi S, Leong-Poi H et al (2020) Effects of empagliflozin on left ventricular remodeling in patients with type 2 diabetes and coronary artery disease: echocardiographic substudy of the EMPA-HEART CardioLink-6 randomized clinical trial. J Am Soc Echocardiogr 33(5):644–646. https://doi.org/10.1016/j.echo.2020.02.005

    Article  PubMed  Google Scholar 

  8. Rau M, Thiele K, Hartmann N et al (2021) Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Cardiovasc Diabetol 20(1):6. https://doi.org/10.1186/s12933-020-01175-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We are indebted to all of those who contributed to the EMPA-HEART CardioLink-6 trial.

Funding

The EMPA-HEART CardioLink-6 trial was supported by an unrestricted investigator-initiated study grant from Boehringer Ingelheim. The study sponsor had no role in the study design, data collection or analysis, interpretation of the findings, writing the manuscript or the decision to submit the manuscript for publication.

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medical Imaging, St Michael’s Hospital, 30 Bond Street, Rm 6-030D, Toronto, ON, M5B 1W8, Canada

    Archana Rai, Marina Pourafkari, Laura Jimenez-Juan, Djeven P. Deva & Andrew T. Yan

  2. University of Toronto, Toronto, Canada

    Archana Rai, Kim A. Connelly, Subodh Verma, C. David Mazer, Idan Roifman, Laura Jimenez-Juan, Yin Ge, Djeven P. Deva & Andrew T. Yan

  3. Terrence Donnelly Heart Center, St Michael’s Hospital, Toronto, Canada

    Kim A. Connelly, Subodh Verma, Yin Ge & Andrew T. Yan

  4. Keenan Research Center, Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Canada

    Kim A. Connelly, Subodh Verma, C. David Mazer, Hwee Teoh, Adrian Quan & Andrew T. Yan

  5. Division of Cardiac Surgery, St Michael’s Hospital, Toronto, Canada

    Subodh Verma, Hwee Teoh & Adrian Quan

  6. Department of Anesthesia, St Michael’s Hospital, Toronto, Canada

    C. David Mazer

  7. Division of Endocrinology and Metabolism, St Michael’s Hospital, Toronto, Canada

    Hwee Teoh

  8. Department of Diagnostic Radiology, HKU-Shenzhen Hospital and Li Ka Shing Faculty of Medicine, The University of Hong Kong, Shenzhen and Hong Kong SAR, China

    Ming-Yen Ng

  9. Schulich Heart Center, Sunnybrook Health Sciences Center, Toronto, Canada

    Idan Roifman & Venkat Ramanan

  10. Queen’s University, Kingston, Canada

    Marina Pourafkari

Authors
  1. Archana Rai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kim A. Connelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Subodh Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. David Mazer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hwee Teoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ming-Yen Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Idan Roifman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Adrian Quan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marina Pourafkari
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Laura Jimenez-Juan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Venkat Ramanan
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yin Ge
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Djeven P. Deva
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Andrew T. Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Djeven P. Deva or Andrew T. Yan.

Ethics declarations

Conflict of interest

Archana Rai, no conflicts. Subodh Verma, Tier 1 Canada Research Chair in Cardiovascular Surgery. Research grant support and/or speaking honoraria from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, EOCI Pharmacomm Ltd, HLS Therapeutics, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, PhaseBio, Sanofi, Sun Pharmaceuticals, and the Toronto Knowledge Translation Working Group. President of the Canadian Medical and Surgical Knowledge Translation Research Group, a federally incorporated not-for-profit physician organization. Hwee Teoh, consulting honoraria from Boehringer Ingelheim and manuscript writing fees for unrelated topics from Merck and Servier. Ming-Yen Ng, research grant support and/or speaking/consulting honoraria from Circle, Bayer, TeraRecon and GE. Idan Roifman, no conflicts. C. David Mazer, research grant support and/or speaking/consulting honoraria from Amgen, AstraZeneca, Boehringer Ingelheim and Octapharma. Kim A Connelly, research grant support and/or speaking/consulting honoraria from Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Edwards, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi, Servier. Djeven P Deva, no conflicts. Adrian Quan, no conflicts. Marina Pourafkari, no conflicts. Laura Jimenez-Juan, no conflicts. Venkat Ramanan, no conflicts. Yin Ge, no conflicts. Andrew T. Yan, research grant support from AstraZeneca.

Ethical statement

This is a substudy of the EMPA-HEART CardioLink-6 trial (NCT02998970), a double-blinded randomized controlled trial (RCT), approved by the Institutional Research Ethics Board.

Informed consent

All participants provided written informed consent.

Additional information

Managed by Massimo Federici.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rai, A., Connelly, K.A., Verma, S. et al. Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial. Acta Diabetol 59, 575–578 (2022). https://doi.org/10.1007/s00592-021-01823-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-021-01823-6

Keywords

Search

Navigation